MedTrace Logo

A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.

NCT05710289 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-07-27

No results posted yet for this study

Summary

The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older

Conditions

Interventions

BIOLOGICAL

Immune Responses

To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510\_004 study.

Sponsors & Collaborators

  • International Vaccine Institute

    collaborator OTHER

  • SK Bioscience Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Santa K Das, MD · Study Principal Investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2024-02-29
Completion
2024-02-29

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05710289 on ClinicalTrials.gov